

CIRM Funded Clinical Trials

A Phase 2 Open-Label, Multi-Center, Randomized, Controlled, Optimal Dose-Finding Study of DCC-UCB in Adults Receiving High Dose Chemotherapy for AML

Disease Area:	Acute Myeloid Leukemia
Investigator:	Colleen Delaney
Institution:	Nohla Therapeutics Inc
CIRM Grant:	CLIN2-09574
Award Value:	\$6,922,109
Trial Sponsor:	Nohla Therapeutics Inc
Trial Stage:	Phase 2
Trial Status:	Not yet recruiting
Targeted Enrollment:	220
ClinicalTrials.gov ID:	NCT03301597



Colleen Delaney

Details:

Nohla Therapeutics is testing a hematopoietic stem cell and progenitor cell therapy called NLA101 to help patients suffering from neutropenia, a condition that leaves people susceptible to deadly infections, after receiving chemotherapy for acute myeloid leukemia (AML). The company is currently launching a Phase 2 trial to test this treatment in adult AML patients that have received high-dose chemotherapy.

Design:

Phase 2 open-label, multi-center, randomized, controlled, dose-finding study of safety and efficacy.

Goal:

Evaluate effect on the rate of infections associated with Chemotherapy-Induced Neutropenia in AML patients and determine optimal dose of cell therapy.

Updates:

Launching

News Releases:

Nohla Therapeutics Awarded \$6.9 Million Grant From The California Institute for Regenerative Medicine

[Contact Trial Sponsor](#)

Source URL: <http://www.cirm.ca.gov/clinical-trial/phase-2-open-label-multi-center-randomized-controlled-optimal-dose-finding-study-0>